Acute Mountain Sickness Clinical Trial
— TAIAOfficial title:
Can Osteopathy and Expiratory Resistance be Used in Prevention and/or Treatment of Acute Mountain Sickness ? a Randomized Controlled Field Study
NCT number | NCT03956472 |
Other study ID # | TAIA |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | June 17, 2017 |
Est. completion date | July 31, 2019 |
Verified date | August 2021 |
Source | Institut de Formation et de Recherche en Médecine de Montagne |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research is to support a hypothesis that osteopathic manual medicine (OMM) and / or a 10 cmH2O end-expiratory pressure (PEEP) could be used in the prevention of acute mountain sickness (AMS). During altitude exposure, an exaggerated hypoxemia and the increase of intracranial pressure are both known to be major physipathological ways of AMS development. The goal of the osteopathic protocol is to release tension on the circulatory structures directly related to cranial circulation and drainage. The main hypothesis is that it could lead to lower intracranial pressure and help reducing AMS signs. Furthermore the investigators would like to define a osteopathic score for individual AMS sensitivity, based on cranial bones mobility. Several studies have shown that using PEEP at altitude (or hypoxia) increases SpO2. As for osteopathy protocol, the investigators would like to apply this experimental condition during real altitude exposure in a randomized controlled protocol.
Status | Terminated |
Enrollment | 50 |
Est. completion date | July 31, 2019 |
Est. primary completion date | October 20, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Healthy - Experienced alpinist - No previous acclimatization Exclusion Criteria: - Heart failure, respiratory failure, kidney failure - Pregnant woman |
Country | Name | City | State |
---|---|---|---|
France | Ifremmont | Chamonix |
Lead Sponsor | Collaborator |
---|---|
Institut de Formation et de Recherche en Médecine de Montagne |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in Lake Louise Score from baseline to altitude continuous exposure. | Signs of acute mountain sickness regarding its severity according the official Lake Louise Score. | mesured and reported every hour during a 10 hours altitude exposure | |
Secondary | Changes in numeric scale of well being from baseline to altitude continuous exposure. | Quantification of general feeling on a scale from 0 (feeling as before ascent) to 10 (worst feeling) | every hour during a 10 hours altitude exposure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04111263 -
Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude
|
N/A | |
Completed |
NCT01842906 -
Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)
|
N/A | |
Completed |
NCT01536288 -
Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness
|
Phase 2 | |
Completed |
NCT00326703 -
Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort
|
N/A | |
Completed |
NCT06310642 -
Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness
|
Phase 4 | |
Completed |
NCT03561675 -
Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years
|
Phase 4 | |
Completed |
NCT00559832 -
Prevention of Acute Mountain Sickness by Intermittent Hypoxia
|
N/A | |
Completed |
NCT01436383 -
Oxidative Stress in Hypobaric Hypoxia
|
N/A | |
Completed |
NCT00603122 -
Acclimatization Mechanisms During Ascent to 7500m
|
N/A | |
Completed |
NCT00627965 -
Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness
|
Phase 4 | |
Completed |
NCT00664001 -
Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness
|
Phase 3 | |
Not yet recruiting |
NCT06145113 -
The Effect of Continuous Positive Pressure Ventilation on Symptoms of Acute Mountain Sickness
|
N/A | |
Recruiting |
NCT05733338 -
The Effects of Intermittent Hypoxia on Acute Hypoxic Injury
|
N/A | |
Completed |
NCT01522326 -
Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness
|
N/A | |
Recruiting |
NCT06393998 -
CO2 Supplement for Treatment of Acute Mountain Sickness
|
N/A | |
Completed |
NCT03270787 -
Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness
|
Phase 1/Phase 2 | |
Completed |
NCT02811016 -
Inhaled Budesonide and Acute Mountain Sickness
|
Phase 1 | |
Recruiting |
NCT00886912 -
Training in Hypoxia to Prevent Acute Mountain Sickness
|
N/A | |
Recruiting |
NCT03621410 -
T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent
|
Phase 2 | |
Active, not recruiting |
NCT01565603 -
Sleep and Cerebral Responses to High Altitude
|
N/A |